Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

PharmaSGP increases sales 15.4% to EUR 32.5m, earnings per share fall to EUR 0.29

PharmaSGP reported a sales rise of 15.41% to EUR 32.5m for the quarter to 30 June 2025 (previous year: EUR 28.2m). Earnings per share fell to EUR 0.29, compared with EUR 0.34 in the same quarter last year. » More on finanzen.net
PharmaSGP Holding SE announces delisting from the Frankfurt Stock Exchange as of August 11, 2025

PharmaSGP Holding SE will delist its shares from the Frankfurt Stock Exchange on August 11, 2025, following approval of the corresponding application. The delisting is related to a delisting acquisition offer by FUTRUE GmbH, with the acceptance period ending on the same day. PharmaSGP also plans to cease trading on other stock exchanges and to continue its growth strategy through expansion and M&A activities. » More on finanzen.net
PharmaSGP in focus after insider purchase by FUTRUE GmbH

PharmaSGP reported directors' dealings after FUTRUE GmbH acquired 6,670 shares at €28.00 each on July 23, 2025. The stock showed little price movement following the announcement and closed slightly lower at €28.40 on the day of the BaFin notification. FUTRUE GmbH had already significantly increased its stake in PharmaSGP in May. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics

In 2025, PHARMASGP HOLDING SE O.N. has already paid €0.05 in dividends. The last payout was in July 2025.

Financials

In the last year, PHARMASGP HOLDING SE O.N. had revenue of €118.84M and net profit of €19.54M

(EUR)	2024	YoY
Revenue	118.84M	17.55%
Gross profit	107.99M	17.85%
Net profit	19.54M	19.14%
EBITDA	39.6M	10.39%

Fundamentals

Metric	Value
Market capitalization	€333.86M
Number of shares	11.51M
52-week high/low	€30.00 - €19.00
Dividends	No
Beta	-0.03
P/E ratio	17.58
PEG ratio	1.78
P/B ratio	10.77
P/S ratio	2.81

Company profile

PharmaSGP Holding SE manufactures over-the-counter drugs, and other healthcare products in Germany. The company's pharmaceutical products include Baldriparan for the treatment of sleep disorders; Spalt, Formigran, and Kamol massage cream for the treatment of different pain conditions; RubaXX pharmaceutical drops for the treatment of rheumatic pain in bones, tendons, and muscles; Restaxil pharmaceutical drops for the treatment of nerve pain in neck and back; Fulminan, a beauty drink for problems in areas, such as eye area, buttocks, or thighs; DESEO pharmaceutical drops for sexual weakness; Neradin, a drug for sexual dysfunction; and TAUMEA, a drug for the treatment of vertigo. It also offers products for the treatment of chronic indications, including pain and other age-related ailments. The company sells its products through pharmacies and wholesalers. It exports its products to European countries comprising Austria, Italy, Belgium, Spain, and France. The company was founded in 2012 and is based in Gräfelfing, Germany.